UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
--------
FORM 8-K/A
--------
AMENDMENT NO. 1 TO
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): March 30, 2006
--------
BrainStorm Cell Therapeutics Inc.
(Exact Name of Registrant as Specified in its Charter)
--------
Washington 333-61610 912061053
(State or Other Jurisdiction (Commission File Number) (IRS Employer
of Incorporation) Identification No.)
1350 Avenue of the Americas
New York, New York 10019
(Address of Principal Executive Offices) (Zip Code)
(212) 557-9000
(Registrant's telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
--------
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
|_| Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
--------------------------------------------------------------------------------
Item 1.01 Entry into a Material Definitive Agreement.
On May 23, 2006, the Company entered into a corrective amendment (the
"Amendment") to the Research and License Agreement (the "Research and License
Agreement") with Ramot at Tel Aviv University Ltd. ("Ramot") dated March 30,
2006, for the sole purpose of correcting Section 7.4 of the Research and License
Agreement to properly reflect the original intent and agreement of the parties.
The corrected provision reduces the amount that the Company will pay Ramot with
respect to sublicense receipts from up to 30% of all sublicense receipts to (a)
25% of sublicense receipts, with respect to sublicenses granted prior to
completion of Phase II Clinical Studies and (b) 20% of sublicense receipts, with
respect to sublicenses granted following completion of Phase II Clinical
Studies. The Amendment is effective as of March 30, 2006. A copy of the Research
and License Agreement was filed with the Securities and Exchange Commission as
Exhibit 10.1 to the Company's Form 8-K filed April 4, 2006.
The foregoing description is subject to, and qualified in its entirety by
the Amendment, which is filed as an exhibit hereto and incorporated herein by
reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
10.1 Amendment Agreement, dated May 23, 2006 between the Registrant and Ramot
at Tel Aviv University Ltd.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
BRAINSTORM CELL THERAPEUTICS INC.
By: /s/ Yoram Drucker
-------------------------------------
Date: May 30, 2006 Yoram Drucker
Chief Operating Officer
(Principal executive officer)
EXHIBIT INDEX
Exhibit No. Description
----------- -----------
10.1 Amendment Agreement, dated May 23, 2006 between the Registrant and
Ramot at Tel Aviv University Ltd.